Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aeterna Zentaris Inc. stock logo
AEZS
Aeterna Zentaris
$3.34
-5.9%
$3.16
$3.96
$12.00
$5.99M1.557,305 shs1,449 shs
Glucose Health, Inc. stock logo
GLUC
Glucose Health
$0.09
-5.9%
$0.09
$0.09
$0.48
$1.58M2.128,536 shs485 shs
American Premium Mining Co. stock logo
HIPH
American Premium Mining
$0.00
$0.00
$0.00
$6.44M2.391.82 million shs50,000 shs
TransCode Therapeutics, Inc. stock logo
RNAZ
TransCode Therapeutics
$6.97
+1.5%
$11.40
$6.15
$1,718.64
$5.81M1.52100,767 shs57,827 shs
20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aeterna Zentaris Inc. stock logo
AEZS
Aeterna Zentaris
0.00%-1.39%+10.25%+24.56%-57.59%
Glucose Health, Inc. stock logo
GLUC
Glucose Health
+2.26%-6.05%+6.88%+0.21%-73.25%
American Premium Mining Co. stock logo
HIPH
American Premium Mining
0.00%0.00%0.00%0.00%0.00%
TransCode Therapeutics, Inc. stock logo
RNAZ
TransCode Therapeutics
-1.43%-2.00%-35.43%-92.68%-99.99%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aeterna Zentaris Inc. stock logo
AEZS
Aeterna Zentaris
N/AN/AN/AN/AN/AN/AN/AN/A
Glucose Health, Inc. stock logo
GLUC
Glucose Health
N/AN/AN/AN/AN/AN/AN/AN/A
American Premium Mining Co. stock logo
HIPH
American Premium Mining
N/AN/AN/AN/AN/AN/AN/AN/A
TransCode Therapeutics, Inc. stock logo
RNAZ
TransCode Therapeutics
3.099 of 5 stars
3.54.00.00.04.20.01.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aeterna Zentaris Inc. stock logo
AEZS
Aeterna Zentaris
0.00
N/AN/AN/A
Glucose Health, Inc. stock logo
GLUC
Glucose Health
0.00
N/AN/AN/A
American Premium Mining Co. stock logo
HIPH
American Premium Mining
0.00
N/AN/AN/A
TransCode Therapeutics, Inc. stock logo
RNAZ
TransCode Therapeutics
3.00
Buy$280.003,917.22% Upside

Current Analyst Ratings Breakdown

Latest GLUC, HIPH, AEZS, and RNAZ Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/16/2025
TransCode Therapeutics, Inc. stock logo
RNAZ
TransCode Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$560.00 ➝ $280.00
3/13/2025
TransCode Therapeutics, Inc. stock logo
RNAZ
TransCode Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$560.00 ➝ $560.00
(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aeterna Zentaris Inc. stock logo
AEZS
Aeterna Zentaris
$2.37M2.52N/AN/A$14.99 per share0.22
Glucose Health, Inc. stock logo
GLUC
Glucose Health
$380K4.15N/AN/AN/A
American Premium Mining Co. stock logo
HIPH
American Premium Mining
$70K0.00N/AN/AN/ANaN
TransCode Therapeutics, Inc. stock logo
RNAZ
TransCode Therapeutics
N/AN/AN/AN/A$86.32 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aeterna Zentaris Inc. stock logo
AEZS
Aeterna Zentaris
-$16.55M-$14.86N/AN/A-760.32%-83.45%-45.76%8/11/2025 (Estimated)
Glucose Health, Inc. stock logo
GLUC
Glucose Health
-$320K-$0.03N/AN/A-82.29%N/AN/AN/A
American Premium Mining Co. stock logo
HIPH
American Premium Mining
N/AN/A0.00N/AN/AN/AN/AN/AN/A
TransCode Therapeutics, Inc. stock logo
RNAZ
TransCode Therapeutics
-$18.55MN/A0.00N/AN/AN/A-649.03%-281.34%N/A

Latest GLUC, HIPH, AEZS, and RNAZ Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/21/2025Q4 2024
TransCode Therapeutics, Inc. stock logo
RNAZ
TransCode Therapeutics
-$2.00-$0.60+$1.40-$2.51$0.30 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aeterna Zentaris Inc. stock logo
AEZS
Aeterna Zentaris
N/AN/AN/AN/AN/A
Glucose Health, Inc. stock logo
GLUC
Glucose Health
N/AN/AN/AN/AN/A
American Premium Mining Co. stock logo
HIPH
American Premium Mining
N/AN/AN/AN/AN/A
TransCode Therapeutics, Inc. stock logo
RNAZ
TransCode Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aeterna Zentaris Inc. stock logo
AEZS
Aeterna Zentaris
N/A
5.94
5.93
Glucose Health, Inc. stock logo
GLUC
Glucose Health
N/AN/AN/A
American Premium Mining Co. stock logo
HIPH
American Premium Mining
N/AN/AN/A
TransCode Therapeutics, Inc. stock logo
RNAZ
TransCode Therapeutics
N/A
1.58
1.58

Institutional Ownership

CompanyInstitutional Ownership
Aeterna Zentaris Inc. stock logo
AEZS
Aeterna Zentaris
0.73%
Glucose Health, Inc. stock logo
GLUC
Glucose Health
N/A
American Premium Mining Co. stock logo
HIPH
American Premium Mining
N/A
TransCode Therapeutics, Inc. stock logo
RNAZ
TransCode Therapeutics
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Aeterna Zentaris Inc. stock logo
AEZS
Aeterna Zentaris
201.79 million1.79 millionNo Data
Glucose Health, Inc. stock logo
GLUC
Glucose Health
147,00017.41 millionN/ANot Optionable
American Premium Mining Co. stock logo
HIPH
American Premium Mining
164.40 billionN/ANot Optionable
TransCode Therapeutics, Inc. stock logo
RNAZ
TransCode Therapeutics
9833,000677,000Not Optionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aeterna Zentaris stock logo

Aeterna Zentaris NASDAQ:AEZS

$3.34 -0.21 (-5.92%)
As of 05/27/2025

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.

Glucose Health stock logo

Glucose Health OTCMKTS:GLUC

$0.09 -0.01 (-5.92%)
As of 09:30 AM Eastern

Glucose Health, Inc. engages in the formulation, manufacturing, marketing, and distribution of soluble fiber infused nutritional beverages. It offers soluble fiber infused powdered iced tea, and flavored drink mixes for pre-diabetic and diabetic persons under the GLUCODOWN brand in North America. The company was formerly known as Bio-Solutions Corp. and changed its name to Glucose Health, Inc. in November 2014. Glucose Health, Inc. was incorporated in 2007 and is based in Bentonville, Arkansas.

American Premium Mining stock logo

American Premium Mining OTCMKTS:HIPH

American Premium Mining Corporation focuses on supporting the blockchain ecosystem through proof-of-work and proof-of-stake mining of cryptocurrencies. The company was formerly known as American Premium Water Corporation and changed its name to American Premium Mining Corporation in May 2022. American Premium Mining Corporation is based in Playa Vista, California.

TransCode Therapeutics stock logo

TransCode Therapeutics NASDAQ:RNAZ

$6.97 +0.10 (+1.46%)
Closing price 04:00 PM Eastern
Extended Trading
$7.06 +0.09 (+1.29%)
As of 07:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. In addition, the company developing TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.